Glucagon like Peptide 1 News and Research

RSS

Exercise, GLP-1 receptor agonist, or combined approach explored in year-long study

Researchers compare the extent of weight loss after one-year termination of active intervention with GLP-1 receptor agonist, exercise, or combination.

29 Feb 2024

New weight loss drug may be an effective strategy for preventing or treating high blood pressure

The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took the medication for about eight months, according to new research published today in Hypertension, an American Heart Association journal.

5 Feb 2024

What does the future hold for obesity medication development?

The safety, clinical implications, and challenges of obesity pharmacotherapies based on entero-pancreatic hormone- treatments.

5 Feb 2024

Study links GLP1 agonists to reduced risk of severe liver disease in diabetic patients

Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet in Sweden published in the journal Gut.

23 Jan 2024

GLP-1R agonist liraglutide rapidly improves insulin sensitivity in pre-diabetics, independent of weight loss

A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in insulin sensitivity.

4 Jan 2024

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

Study demonstrates that combining dapagliflozin and semaglutide significantly improves glycemic control and other health parameters in type 2 diabetes patients, outperforming dapagliflozin alone.

3 Jan 2024

Adherence to second-line drugs for Type 2 diabetes can be hit or miss, study reports

Most patients with Type 2 diabetes will end up needing to add a second-line medication after metformin -; the go-to primary drug for glucose management -; to control their blood sugar levels.

12 Dec 2023

New insights into how anti-obesity drugs could help prevent kidney disease

Data from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found to be so effective.

8 Dec 2023

A class of diabetes medications may reduce the risk of colorectal cancer

A groundbreaking study by researchers at Case Western Reserve University suggests a class of medications used to treat type 2 diabetes may also reduce the risk of colorectal cancer (CRC).

7 Dec 2023

Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity

The impact of semaglutide and tirzepatide and glucagon-like peptide-1 receptor agonist medications on alcohol consumption.

1 Dec 2023

Exploring 'food noise': Study sheds light on eating thoughts and obesity treatment breakthroughs

Study delves into the concept of 'food noise,' referring to persistent thoughts about eating, and assesses its impact on eating behaviors and obesity treatments. It explores how GLP-1RAs, a class of drugs used for weight management, might influence food cue reactivity, potentially offering new insights into obesity treatment and the psychological aspects of eating behaviors.

30 Nov 2023

New study links DNA methylation in GLP1R gene to obesity without metabolic disorders

The study investigates the role of epigenetic changes in GLP1R gene polymorphisms on metabolically healthy obesity (MHO), revealing that apart from genetic variations, DNA methylation significantly influences the occurrence of MHO.

20 Nov 2023

Citrus compounds show zesty promise in type 2 diabetes management

Citrus compounds show promise in type 2 diabetes management, reducing blood glucose and mitigating metabolic complications without a clear threshold in humans for bioflavonoid efficacy.

2 Nov 2023

Novel GLP-1 receptor agonists offer hope for long-lasting diabetes treatment

In a study published in Scientific Reports, researchers engineer long-lasting GLP-1 receptor agonists by fusing GLP-1 with an HSA-binding protein. These chimeric molecules show promise for the treatment of type 2 diabetes due to their stability, functionality, and high affinity for the GLP-1 receptor and human serum albumin.

22 Oct 2023

Exploring the impact of solid oat polar lipid-enriched breakfasts on metabolic health

Researchers investigate if oat polar lipid compounds improve glucose tolerance, gut hormonal responses, and triglyceridemia.

20 Oct 2023

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

The study reveals a significant increase in the usage of GLP-1 receptor agonists, particularly Ozempic and Trulicity, for weight management and Type 2 diabetes in the U.S. from 2014 to 2022. Amidst rapid growth and shortages, the paper calls for evidence-based decision-making to ensure stable medication supply and effective treatment.

17 Oct 2023

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

In a groundbreaking 84-week-long study, researchers found that tirzepatide, a medication initially designed for treating type 2 diabetes, significantly bolstered weight loss in overweight and obese patients already on intensive lifestyle programs. While the drug showed promise in further reducing body weight and improving cardiometabolic factors, mild to moderate gastrointestinal side effects were the most common drawback.

16 Oct 2023

GLP-1 weight loss drugs linked to heightened GI risks, says new study

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

5 Oct 2023

GLP-1 agonists linked to higher risk for gastrointestinal complications

They're being hailed as an effective way to lose weight, but diabetes drugs like Ozempic may come with a heightened risk of severe gastrointestinal problems.